DCR

malignant mesothelioma (mMS) - 1st line (L1) malignant mesothelioma (mMS) - 1st line (L1)

versus pemetrexed plus platin
nivolumab plus ipilimumab vs. pemetrexed plus platin 1 certainty unassessable-39%

malignant mesothelioma (mMS) - 2nd line (L2) malignant mesothelioma (mMS) - 2nd line (L2)

versus placebo
nivolumab alone vs. placebo 1 -
tremelimumab vs. placebo 1 certainty unassessable+39%